STAT3 in CD8+ T cells inhibits their tumor accumulation by downregulating CXCR3/CXCL10 axis

Cancer Immunology Research

Volumn 3, Issue 8, 2015, Pages 864-870

  Yue, Chanyu ^a   Shen, Shudan ^a   Deng, Jiehui ^a   Priceman, Saul J ^a   Li, Wenzhao ^a   Huang, Austin ^a   Yu, Hua ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; STAT3 PROTEIN; CHEMOKINE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CD8+ T LYMPHOCYTE; CELL HOMING; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IN VITRO STUDY; MACROPHAGE; MALE; MELANOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; ANIMAL; CELL MOTION; DISEASE MODEL; EXPERIMENTAL MELANOMA; GENE INACTIVATION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CHEMOKINE CXCL10; CHEMOKINES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GENE KNOCKOUT TECHNIQUES; HUMANS; INTERFERON-GAMMA; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA, EXPERIMENTAL; MICE; MICE, TRANSGENIC; MYELOID CELLS; NEOPLASMS; RECEPTORS, CXCR3; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84962033748     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0014     Document Type: Article

References (25)

1. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007;117:1466-76.
2. June CH. Principles of adoptive T cell cancer therapy. J Clin Invest 2007;117:1204-12.
3. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005;11:1314-21.
4. Zou W. Regulatory T cells, tumourimmunity and immunotherapy. Nat Rev Immunol 2006;6:295-307.
5. Frank DA. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett 2007;251:199-210.
6. Herrmann A, Kortylewski M, Kujawski M, Zhang C, Reckamp K, Armstrong B, et al. Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res 2010;70:7455-64.
7. Kujawski M, Zhang C, Herrmann A, Reckamp K, Scuto A, Jensen M, et al. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res 2010;70:9599-610.
8. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 2014;14:736-46.
9. Priceman SJ, Shen S, Wang L, Deng J, Yue C, Kujawski M, et al. S1PR1 is crucial for accumulation of regulatory T cells in tumors via STAT3. Cell Reports 2014;6:992-9.
10. Lee H, Deng J, Kujawski M, Yang C, Liu Y, Herrmann A, et al. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med 2010;16:1421-8.
11. Johrer K, Pleyer L, Olivier A, Maizner E, Zelle-Rieser C, Greil R. Tumourimmune cell interactions modulated by chemokines. Expert Opin Biol Ther 2008;8:269-90.
12. Mule JJ, Custer M, Averbook B, Yang JC, Weber JS, Goeddel DV, et al. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Human Gene Ther 1996;7:1545-53.
13. Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y, Zhang M, et al. Transduction of tumor-specificTcells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res 2010;16:5458-68.
14. Bromley SK, Mempel TR, Luster AD. Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol 2008;9:970-80.
15. Sung JH, Zhang H, Moseman EA, Alvarez D, Iannacone M, Henrickson SE, et al. Chemokine guidance of central memory T cells is critical for antiviral recall responses in lymph nodes. Cell 2012;150:1249-63.
16. Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 2011;89:207-15.
17. Wu X, Lahiri A, Haines GK 3rd, Flavell RA, Abraham C. NOD2 regulates CXCR3-dependent CD8+ T cell accumulation in intestinal tissues with acute injury. J Immunol 2014;192:3409-18.
18. Kondo T, Ito F, Nakazawa H, Horita S, Osaka Y, Toma H. High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma. J Urol 2004;171:2171-5.
19. Mullins IM, Slingluff CL, Lee JK, Garbee CF, Shu J, Anderson SG, et al. CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res 2004;64:7697-701.
20. Ma B, Khazali A, Wells A. CXCR3 in carcinoma progression. Histol Histopathol 2015;11594.
21. Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res 2012;72:5209-18.
22. Shin SY, Nam JS, Lim Y, Lee YH. TNFalpha-exposed bone marrow-derived mesenchymal stem cells promote locomotion of MDA-MB-231 breast cancer cells through transcriptional activation of CXCR3 ligand chemokines. J Biol Chem 2010;285:30731-40.
23. Sharma RK, Chheda Z, Jala VR, Haribabu B. Expression of leukotriene B (4) receptor-1 on CD8 (+) T cells is required for their migration into tumors to elicit effective antitumor immunity. J Immunol 2013;191:3462-70.
24. Scheele JS, Marks RE, Boss GR. Signaling by small GTPases in the immune system. Immunol Rev 2007;218:92-101.
25. Ramsay AG, Evans R, Kiaii S, Svensson L, Hogg N, Gribben JG. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood 2013;121:2704-14.